RU2011112362A - Твердые препаративные формы оспемифена - Google Patents
Твердые препаративные формы оспемифена Download PDFInfo
- Publication number
- RU2011112362A RU2011112362A RU2011112362/15A RU2011112362A RU2011112362A RU 2011112362 A RU2011112362 A RU 2011112362A RU 2011112362/15 A RU2011112362/15 A RU 2011112362/15A RU 2011112362 A RU2011112362 A RU 2011112362A RU 2011112362 A RU2011112362 A RU 2011112362A
- Authority
- RU
- Russia
- Prior art keywords
- dosage form
- granular materials
- form according
- ospemifene
- wet granulation
- Prior art date
Links
- 239000007787 solid Substances 0.000 title 1
- 239000002552 dosage form Substances 0.000 claims abstract 14
- 239000008187 granular material Substances 0.000 claims abstract 13
- LUMKNAVTFCDUIE-VHXPQNKSSA-N ospemifene Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-VHXPQNKSSA-N 0.000 claims abstract 9
- 229960003969 ospemifene Drugs 0.000 claims abstract 9
- 238000000034 method Methods 0.000 claims abstract 7
- 238000005550 wet granulation Methods 0.000 claims abstract 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 6
- 239000007884 disintegrant Substances 0.000 claims abstract 5
- 239000000843 powder Substances 0.000 claims abstract 5
- 150000003839 salts Chemical class 0.000 claims abstract 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract 4
- 238000009472 formulation Methods 0.000 claims abstract 4
- 239000000203 mixture Substances 0.000 claims abstract 4
- 239000008109 sodium starch glycolate Substances 0.000 claims abstract 4
- 229940079832 sodium starch glycolate Drugs 0.000 claims abstract 4
- 229920003109 sodium starch glycolate Polymers 0.000 claims abstract 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims abstract 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims abstract 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims abstract 2
- 229920002472 Starch Polymers 0.000 claims abstract 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000000783 alginic acid Substances 0.000 claims abstract 2
- 235000010443 alginic acid Nutrition 0.000 claims abstract 2
- 229960001126 alginic acid Drugs 0.000 claims abstract 2
- 229920000615 alginic acid Polymers 0.000 claims abstract 2
- 150000004781 alginic acids Chemical class 0.000 claims abstract 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims abstract 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims abstract 2
- 229940105329 carboxymethylcellulose Drugs 0.000 claims abstract 2
- 239000005018 casein Substances 0.000 claims abstract 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims abstract 2
- 229960000913 crospovidone Drugs 0.000 claims abstract 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims abstract 2
- 238000004090 dissolution Methods 0.000 claims abstract 2
- 239000012458 free base Substances 0.000 claims abstract 2
- 229920000609 methyl cellulose Polymers 0.000 claims abstract 2
- 239000001923 methylcellulose Substances 0.000 claims abstract 2
- 235000010981 methylcellulose Nutrition 0.000 claims abstract 2
- 229960002900 methylcellulose Drugs 0.000 claims abstract 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims abstract 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims abstract 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract 2
- 229940069328 povidone Drugs 0.000 claims abstract 2
- 239000007909 solid dosage form Substances 0.000 claims abstract 2
- 229940032147 starch Drugs 0.000 claims abstract 2
- 239000008107 starch Substances 0.000 claims abstract 2
- 235000019698 starch Nutrition 0.000 claims abstract 2
- 239000002245 particle Substances 0.000 claims 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Твердая лекарственная препаративная форма, включающая гранулированные материалы, содержащие от 30 до 90 мг оспемифена или его фармацевтически приемлемой соли в комбинации с одним или несколькими внутригранулярными эксципиентами, где, по меньшей мере, один внутригранулярный эксципиент представляет собой разрыхлитель. ! 2. Лекарственная препаративная форма по п.1, где разрыхлитель присутствует в количестве от 0,1 до 10 мас.% от массы гранулированных материалов, при этом по меньшей мере 80% препаративной формы растворяется в течение 30 мин после начала тестирования указанной препаративной формы растворением при рН 9,8 в соответствии с лопастным способом по 24-й Фармакопее США. ! 3. Лекарственная препаративная форма по п.1 или 2, где оспемифен находится в виде свободного основания. ! 4. Лекарственная препаративная форма по п.1 или 2, где разрыхлитель выбран из группы, состоящей из повидона, кросповидона, карбоксиметилцеллюлозы, метилцеллюлозы, альгиновой кислоты, кроскармеллозы натрия, натрия крахмалгликолята, крахмала, формальдегид-казеина или их комбинаций. ! 5. Лекарственная препаративная форма по п.4, где разрыхлитель представляет собой натрия крахмалгликолят. !6. Лекарственная препаративная форма по любому из пп.1, 2 или 5, где гранулированные материалы изготовлены влажным гранулированием. ! 7. Лекарственная препаративная форма по п.3, где гранулированные материалы изготовлены влажным гранулированием. !8. Лекарственная препаративная форма по п.4, где гранулированные материалы изготовлены влажным гранулированием. ! 9. Способ приготовления оспемифена или его фармацевтически приемлемой соли, предусматривающий гранулиров
Claims (12)
1. Твердая лекарственная препаративная форма, включающая гранулированные материалы, содержащие от 30 до 90 мг оспемифена или его фармацевтически приемлемой соли в комбинации с одним или несколькими внутригранулярными эксципиентами, где, по меньшей мере, один внутригранулярный эксципиент представляет собой разрыхлитель.
2. Лекарственная препаративная форма по п.1, где разрыхлитель присутствует в количестве от 0,1 до 10 мас.% от массы гранулированных материалов, при этом по меньшей мере 80% препаративной формы растворяется в течение 30 мин после начала тестирования указанной препаративной формы растворением при рН 9,8 в соответствии с лопастным способом по 24-й Фармакопее США.
3. Лекарственная препаративная форма по п.1 или 2, где оспемифен находится в виде свободного основания.
4. Лекарственная препаративная форма по п.1 или 2, где разрыхлитель выбран из группы, состоящей из повидона, кросповидона, карбоксиметилцеллюлозы, метилцеллюлозы, альгиновой кислоты, кроскармеллозы натрия, натрия крахмалгликолята, крахмала, формальдегид-казеина или их комбинаций.
5. Лекарственная препаративная форма по п.4, где разрыхлитель представляет собой натрия крахмалгликолят.
6. Лекарственная препаративная форма по любому из пп.1, 2 или 5, где гранулированные материалы изготовлены влажным гранулированием.
7. Лекарственная препаративная форма по п.3, где гранулированные материалы изготовлены влажным гранулированием.
8. Лекарственная препаративная форма по п.4, где гранулированные материалы изготовлены влажным гранулированием.
9. Способ приготовления оспемифена или его фармацевтически приемлемой соли, предусматривающий гранулирование оспемифена или его фармацевтически приемлемой соли в виде множества частиц, где 90% частиц оспемифена имеют размер менее, чем 50 мкм, и 50% частиц оспемифена имеет размер менее, чем 15 мкм, с одним или несколькими внутригранулярными эксципиентами.
10. Способ по п.9, где гранулированные материалы изготовлены влажным гранулированием.
11. Способ по п.9 или 10, где внутригранулярный эксципиент представляет собой разрыхлитель.
12. Способ по п.11, где разрыхлитель присутствует в количестве от 0,1 до 10 мас.% гранулированных материалов.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/783,024 US8642079B2 (en) | 2004-02-23 | 2004-02-23 | Solid formulations of ospemifene |
| US10/783,024 | 2004-02-23 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006133902/15A Division RU2423113C2 (ru) | 2004-02-23 | 2005-01-19 | Твердые препаративные формы оспемифена |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2011112362A true RU2011112362A (ru) | 2012-10-10 |
| RU2675624C2 RU2675624C2 (ru) | 2018-12-21 |
Family
ID=34861126
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006133902/15A RU2423113C2 (ru) | 2004-02-23 | 2005-01-19 | Твердые препаративные формы оспемифена |
| RU2011112362A RU2675624C2 (ru) | 2004-02-23 | 2005-01-19 | Твердые препаративные формы оспемифена |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006133902/15A RU2423113C2 (ru) | 2004-02-23 | 2005-01-19 | Твердые препаративные формы оспемифена |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8642079B2 (ru) |
| EP (2) | EP1718288B1 (ru) |
| JP (1) | JP4993203B2 (ru) |
| CN (1) | CN1953741B (ru) |
| AT (1) | ATE506054T1 (ru) |
| AU (1) | AU2005215174B2 (ru) |
| BR (1) | BRPI0507897B8 (ru) |
| CA (1) | CA2554695C (ru) |
| CY (1) | CY1111689T1 (ru) |
| DE (1) | DE602005027540D1 (ru) |
| DK (1) | DK1718288T3 (ru) |
| ES (1) | ES2364970T3 (ru) |
| MX (1) | MXPA06009546A (ru) |
| NO (1) | NO341573B1 (ru) |
| PL (1) | PL1718288T3 (ru) |
| PT (1) | PT1718288E (ru) |
| RU (2) | RU2423113C2 (ru) |
| SI (1) | SI1718288T1 (ru) |
| WO (1) | WO2005079777A1 (ru) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60234812D1 (de) | 2001-01-29 | 2010-02-04 | Shionogi & Co | Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält |
| US8236861B2 (en) | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
| US8642079B2 (en) | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
| CA2565134C (en) | 2004-05-04 | 2013-05-21 | Veli-Matti Lehtola | Novel oral formulations of ospemifene |
| US8758821B2 (en) * | 2004-05-04 | 2014-06-24 | Hormos Medical Ltd. | Oral formulations of ospemifene |
| NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
| BRPI0618510A2 (pt) * | 2005-11-09 | 2011-09-06 | Hormos Medical Ltd | formulação medicamentosa lìquida ou semi-sólida |
| CA2563690C (en) * | 2006-10-12 | 2014-10-07 | Pharmascience Inc. | Pharmaceutical compositions comprising intra- and extra- granular fractions |
| JP5363344B2 (ja) | 2007-02-14 | 2013-12-11 | ホルモス メディカル リミテッド | 治療に有用なトリフェニルブテン誘導体の調製方法 |
| US7504530B2 (en) | 2007-02-14 | 2009-03-17 | Hormos Medical Ltd. | Methods for the preparation of fispemifene from ospemifene |
| MX2010010383A (es) * | 2008-04-01 | 2010-12-14 | Ocean 1 806 Llc | Formulaciones orodispersables de inhibidores de fosfodiesterasa-5 (pde-5). |
| WO2014060639A1 (en) | 2012-10-19 | 2014-04-24 | Fermion Oy | A process for the preparation of ospemifene |
| CN104788300B (zh) * | 2014-01-22 | 2017-01-11 | 南京华威医药科技开发有限公司 | 欧司哌米芬多晶型 |
| US20160000732A1 (en) * | 2014-07-02 | 2016-01-07 | Cadila Healthcare Limited | Oral pharmaceutical compositions of ospemifene |
| US20160022604A1 (en) * | 2014-07-23 | 2016-01-28 | Cadila Healthcare Limited | Directly compressed ospemifene compositions |
| US10138190B2 (en) | 2015-01-09 | 2018-11-27 | Glenmark Pharmaceuticals Limited | Process for preparation of ospemifene |
| MX2017011469A (es) * | 2015-03-10 | 2018-01-23 | Shionogi Inc | Dispersiones sólidas. |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| PL3573472T3 (pl) * | 2017-01-24 | 2025-02-24 | OmniGen Research, L.L.C. | Granulowany suplement paszowy oraz sposoby wytwarzania i zastosowania |
| AU2021276611A1 (en) | 2020-05-18 | 2022-12-15 | Orexo Ab | New pharmaceutical composition for drug delivery |
| JP2024541470A (ja) | 2021-11-25 | 2024-11-08 | オレクソ・アクチエボラゲット | アドレナリンを含む医薬組成物 |
| GB202117016D0 (en) | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4117121A (en) * | 1977-04-22 | 1978-09-26 | Hoffmann-La Roche Inc. | Method of increasing bile flow and decreasing lipid levels |
| FI100692B (fi) | 1994-05-24 | 1998-02-13 | Leiras Oy | Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä |
| GB9418067D0 (en) * | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
| US6562862B1 (en) * | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
| US5597582A (en) * | 1995-09-12 | 1997-01-28 | Sanofi | Oral gel capsule formulation of 1,2,4-benzotriazine oxides |
| AU718417B2 (en) * | 1995-11-14 | 2000-04-13 | Stockhausen Gmbh & Co. Kg | Water additive and method for fire prevention and fire extinguishing |
| GB9604577D0 (en) | 1996-03-04 | 1996-05-01 | Orion Yhtymae Oy | Serum cholesterol lowering agent |
| FI101305B1 (fi) * | 1996-03-18 | 1998-05-29 | Map Medical Technologies Oy | Radiofarmaseuttisena aineena käyttökelpoiset radiojodatut bentsodiatsepiini-johdannaiset ja niiden käyttö diagnostiikassa |
| DE19653736C2 (de) * | 1996-12-12 | 2002-11-21 | Lancaster Group Gmbh | Kosmetisches Präparat mit Peptidzusatz |
| RU2112504C1 (ru) * | 1996-12-24 | 1998-06-10 | Открытое акционерное общество "Нижегородский химико-фармацевтический завод" | Средство для лечения заболеваний предстательной железы "витапрост" |
| JP2002521322A (ja) * | 1998-07-23 | 2002-07-16 | ノボ ノルディスク アクティーゼルスカブ | 安定な医薬製剤の製造のための湿式顆粒化方法 |
| US6525084B2 (en) * | 1998-07-23 | 2003-02-25 | Novo Nordisk A/S | Stable pharmaceutical formulation |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6245352B1 (en) * | 1999-04-27 | 2001-06-12 | Eli Lilly And Company | Pharmaceutical formulation |
| US6245819B1 (en) * | 2000-07-21 | 2001-06-12 | Hormos Medical Oy, Ltd. | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
| US6838484B2 (en) * | 2000-08-24 | 2005-01-04 | University Of Tennessee Research Foundation | Formulations comprising selective androgen receptor modulators |
| WO2002056903A2 (en) * | 2001-01-17 | 2002-07-25 | Praecis Pharmaceuticals Inc. | Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators |
| RU2177802C1 (ru) * | 2001-01-25 | 2002-01-10 | Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" | Тетрапептид, регулирующий функции предстательной железы, фармакологическое средство на его основе и способ его применения |
| US20030055075A1 (en) * | 2001-07-13 | 2003-03-20 | Rubsamen Reid M. | Programmable controlled release injectable opioid formulation |
| JP2003137814A (ja) | 2001-08-10 | 2003-05-14 | Takeda Chem Ind Ltd | ＧｎＲＨアゴニストの併用剤 |
| HUP0202719A3 (en) * | 2001-08-21 | 2006-01-30 | Pfizer Prod Inc | Pharmaceutical compositions for the treatment of female sexual dysfunctions |
| PT1509215E (pt) | 2002-06-06 | 2007-01-31 | Hormos Medical Ltd | Tratamento ou profilaxia da atrofia urogenital e seus sintomas em mulheres |
| US7407965B2 (en) * | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
| US8236861B2 (en) * | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
| US8642079B2 (en) | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
| US20060105045A1 (en) * | 2004-11-08 | 2006-05-18 | Buchanan Charles M | Cyclodextrin solubilizers for liquid and semi-solid formulations |
| EA200700760A1 (ru) * | 2007-04-27 | 2008-08-29 | Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") | Средство для лечения заболеваний предстательной железы |
| RU2430733C2 (ru) * | 2009-10-08 | 2011-10-10 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Фармацевтическая композиция для лечения заболеваний предстательной железы (варианты) |
-
2004
- 2004-02-23 US US10/783,024 patent/US8642079B2/en active Active
-
2005
- 2005-01-19 CA CA2554695A patent/CA2554695C/en not_active Expired - Lifetime
- 2005-01-19 AU AU2005215174A patent/AU2005215174B2/en not_active Ceased
- 2005-01-19 MX MXPA06009546A patent/MXPA06009546A/es active IP Right Grant
- 2005-01-19 RU RU2006133902/15A patent/RU2423113C2/ru active
- 2005-01-19 EP EP05708125A patent/EP1718288B1/en not_active Expired - Lifetime
- 2005-01-19 PL PL05708125T patent/PL1718288T3/pl unknown
- 2005-01-19 PT PT05708125T patent/PT1718288E/pt unknown
- 2005-01-19 WO PCT/FI2005/000037 patent/WO2005079777A1/en not_active Ceased
- 2005-01-19 CN CN2005800049727A patent/CN1953741B/zh not_active Expired - Fee Related
- 2005-01-19 ES ES05708125T patent/ES2364970T3/es not_active Expired - Lifetime
- 2005-01-19 RU RU2011112362A patent/RU2675624C2/ru not_active Application Discontinuation
- 2005-01-19 BR BRPI0507897A patent/BRPI0507897B8/pt not_active IP Right Cessation
- 2005-01-19 DE DE602005027540T patent/DE602005027540D1/de not_active Expired - Lifetime
- 2005-01-19 AT AT05708125T patent/ATE506054T1/de active
- 2005-01-19 DK DK05708125.9T patent/DK1718288T3/da active
- 2005-01-19 SI SI200531330T patent/SI1718288T1/sl unknown
- 2005-01-19 JP JP2007500233A patent/JP4993203B2/ja not_active Expired - Lifetime
- 2005-01-19 EP EP10180718A patent/EP2286806A1/en not_active Withdrawn
-
2006
- 2006-09-20 NO NO20064262A patent/NO341573B1/no unknown
-
2011
- 2011-07-14 CY CY20111100689T patent/CY1111689T1/el unknown
-
2014
- 2014-01-30 US US14/168,842 patent/US20140220118A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0507897B8 (pt) | 2021-05-25 |
| EP2286806A1 (en) | 2011-02-23 |
| CN1953741A (zh) | 2007-04-25 |
| DK1718288T3 (da) | 2011-08-01 |
| DE602005027540D1 (de) | 2011-06-01 |
| NO20064262L (no) | 2006-09-20 |
| JP4993203B2 (ja) | 2012-08-08 |
| CN1953741B (zh) | 2011-03-30 |
| EP1718288A1 (en) | 2006-11-08 |
| ATE506054T1 (de) | 2011-05-15 |
| CA2554695C (en) | 2013-03-05 |
| MXPA06009546A (es) | 2007-04-10 |
| US20140220118A1 (en) | 2014-08-07 |
| AU2005215174A1 (en) | 2005-09-01 |
| CY1111689T1 (el) | 2015-10-07 |
| WO2005079777A1 (en) | 2005-09-01 |
| JP2007523210A (ja) | 2007-08-16 |
| PL1718288T3 (pl) | 2011-10-31 |
| NO341573B1 (no) | 2017-12-04 |
| ES2364970T3 (es) | 2011-09-19 |
| BRPI0507897B1 (pt) | 2018-10-09 |
| RU2423113C2 (ru) | 2011-07-10 |
| SI1718288T1 (sl) | 2011-09-30 |
| RU2006133902A (ru) | 2008-03-27 |
| PT1718288E (pt) | 2011-07-25 |
| EP1718288B1 (en) | 2011-04-20 |
| CA2554695A1 (en) | 2005-09-01 |
| RU2675624C2 (ru) | 2018-12-21 |
| US8642079B2 (en) | 2014-02-04 |
| BRPI0507897A (pt) | 2007-07-24 |
| AU2005215174B2 (en) | 2010-06-03 |
| US20050187301A1 (en) | 2005-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011112362A (ru) | Твердые препаративные формы оспемифена | |
| ES2205000T5 (es) | Composición farmacéutica que contiene irbesartán | |
| ES2311442T1 (es) | Dosis en forma oral. | |
| RU2017133990A (ru) | Фармацевтические лекарственные формы ингибитора тирозинкиназы брутона | |
| KR101815722B1 (ko) | 톨밥탄 고체 분산물 및 그의 제조 방법 | |
| JP2009545560A5 (ru) | ||
| JP2009537478A5 (ru) | ||
| JP2008525335A (ja) | 経口投与できる固体の放出改変型医薬投与形 | |
| FI3150200T3 (fi) | Menetelmä sglt-2-inhibiittorin ja metformiinin sisältävän tabletin valmistamiseksi | |
| KR20180109992A (ko) | Jak 키나아제 억제제 또는 약학적으로 허용가능한 그의 염을 함유하는 약학적 조성물 | |
| JP2007523210A5 (ru) | ||
| KR20090018843A (ko) | 인터류킨-1 베타 전환효소 억제제의 경구용 조절 방출 제제 | |
| CN110123781A (zh) | 含有药物的中空颗粒 | |
| WO2015110952A1 (en) | Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof | |
| CA2696977A1 (en) | Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof | |
| EP2740471A1 (en) | Oral pharmaceutical composition comprising dabigatran etexilate | |
| RU2008110489A (ru) | Фармацевтическая композиция метформина с длительным высвобождением и способ ее получения | |
| KR20010032129A (ko) | 고용량 약물 로딩 속효성 및 변형 방출형 경구 투여용제형 및 그의 제조 방법 | |
| JP2016512845A (ja) | ソバプレビル錠剤 | |
| WO2014058047A1 (ja) | カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法 | |
| CN102846573B (zh) | 水飞蓟宾双层缓释片及其制备方法 | |
| CN104254321A (zh) | 稳定性提高的药物制剂 | |
| JP2016539109A (ja) | イソニアジドの顆粒およびリファペンチンの顆粒を含むコーティング錠の形態の抗結核性の安定な医薬組成物ならびにその製造方法 | |
| WO2010089775A2 (en) | Improved drug dosage form for controlled delivery of one or more pharmaceutically active agent | |
| CN104000821B (zh) | 含有替米沙坦和苯磺酸氨氯地平的口服双层片剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20171010 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20181011 |